HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HOWL

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/11/20	22 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/11/07	23 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/11/07	23 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/11/07	23 : 02	GlobeNewswire Inc.	Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/11/07	23 : 00	GlobeNewswire Inc.	Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/10/31	21 : 00	GlobeNewswire Inc.	Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/10/04	22 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/09/03	21 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/08/08	20 : 21	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/08/08	20 : 12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/08/08	20 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/08/08	20 : 05	GlobeNewswire Inc.	Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/06/25	20 : 00	GlobeNewswire Inc.	Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/06/03	20 : 56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/06/01	22 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/30	21 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/29	05 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/25	08 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/25	08 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/25	08 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/25	08 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/24	06 : 00	GlobeNewswire Inc.	Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/05/03	20 : 00	GlobeNewswire Inc.	Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/04/24	23 : 05	GlobeNewswire Inc.	Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/04/23	21 : 00	GlobeNewswire Inc.	Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/04/06	05 : 30	GlobeNewswire Inc.	Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/04/05	05 : 30	GlobeNewswire Inc.	Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/03/07	21 : 22	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/03/07	21 : 15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:HOWL	Werewolf Therapeutics Inc
2024/03/07	21 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOWL	Werewolf Therapeutics Inc